Lexston Life Sciences Corp. (LEXTF)
USD 0.13
(83.92%)
USD 0.13
(83.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -648.32 Thousand CAD | 22.98% |
| 2023 | -648.32 Thousand CAD | 38.73% |
| 2022 | -1.88 Million CAD | -1637.85% |
| 2021 | -479.81 Thousand CAD | -1362.58% |
| 2020 | -6480.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -105.79 Thousand CAD | -37.12% |
| 2024 Q4 | -106.42 Thousand CAD | 70.93% |
| 2024 Q2 | -131.6 Thousand CAD | -24.39% |
| 2024 Q3 | -366.11 Thousand CAD | -178.19% |
| 2023 Q4 | -49.15 Thousand CAD | 83.52% |
| 2023 FY | - CAD | 38.73% |
| 2023 Q3 | -298.34 Thousand CAD | 21.69% |
| 2023 Q2 | -380.98 Thousand CAD | -35.77% |
| 2023 Q1 | -280.61 Thousand CAD | -283.6% |
| 2022 FY | - CAD | -1637.85% |
| 2022 Q2 | -633.89 Thousand CAD | -17.14% |
| 2022 Q1 | -541.13 Thousand CAD | 0.0% |
| 2022 Q3 | -326.38 Thousand CAD | 48.51% |
| 2022 Q4 | 152.84 Thousand CAD | 146.83% |
| 2021 FY | - CAD | -1362.58% |
| 2021 Q3 | 110.67 Thousand CAD | 248.64% |
| 2021 Q2 | -74.46 Thousand CAD | 0.0% |
| 2020 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.37 Million USD | 96.268% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 83.309% |
| CSL Limited | 4.78 Billion USD | 100.014% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 100.689% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 30.805% |
| BioStem Technologies, Inc. | -7.55 Million USD | 91.417% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 62.953% |
| Qrons Inc. | -40.08 Thousand USD | -1517.534% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 222.921% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.828% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 90.947% |
| Skye Bioscience, Inc. | -13.54 Million USD | 95.214% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -76.549% |
| Rebus Holdings, Inc. | -951 Thousand USD | 31.827% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 95.915% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.739% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2.517% |
| Adynxx, Inc. | - USD | Infinity% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 99.087% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 89.065% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -171.095% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.989% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 75.484% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 57.793% |
| Mesoblast Limited | -62.38 Million USD | 98.961% |
| Marizyme, Inc. | -34.28 Million USD | 98.109% |
| Genus plc | 73.7 Million USD | 100.88% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 90.194% |
| Pharming Group N.V. | 9.87 Million USD | 106.564% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 56.413% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 81.722% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 92.609% |
| ContraFect Corporation | -64.99 Million USD | 99.003% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 85.676% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 53.751% |
| IMV Inc. | -35.52 Million USD | 98.175% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 72.101% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -25.148% |
| ONE Bio Corp. | 13.61 Million USD | 104.763% |
| Accustem Sciences Inc. | -3.74 Million USD | 82.695% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 98.656% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 48.835% |
| Q BioMed Inc. | -617.62 Thousand USD | -4.97% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 118.15% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 71.621% |
| Biomind Labs Inc. | -1.03 Million USD | 37.333% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 98.364% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 77.585% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 9741.939% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -2493.296% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 74.087% |
| GB Sciences, Inc. | -1.41 Million USD | 54.34% |
| Alpha Cognition Inc. | -9.7 Million USD | 93.32% |
| HST Global, Inc. | -5303.00 USD | -12125.608% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 68.482% |
| Halberd Corporation | -74.27 Thousand USD | -772.823% |
| Enzolytics Inc. | -2.12 Million USD | 69.448% |
| Agentix Corp. | -1.37 Million USD | 52.738% |
| Resverlogix Corp. | -11.74 Million USD | 94.479% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 78.834% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -216.02 Million USD | 99.7% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 153.272% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 107.323% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 56.747% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 271.132% |
| AVAX Technologies, Inc. | -6.11 Million USD | 89.394% |
| Zenith Capital Corp. | -8.6 Million USD | 92.467% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -3621.509% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 73.5% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -268.315% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 66.249% |
| Kadimastem Ltd | -2.62 Million USD | 75.296% |
| Helix BioMedix, Inc. | -1.04 Million USD | 38.037% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -258.016% |
| LadRx Corporation | 412.28 Thousand USD | 257.252% |
| Cell Source, Inc. | -4.27 Million USD | 84.826% |
| Regen BioPharma, Inc. | 1.46 Million USD | 144.225% |
| NovAccess Global Inc. | -1.03 Million USD | 37.348% |
| Affymax, Inc. | -14.29 Million USD | 95.465% |
| Itoco Inc. | -1.86 Million USD | 65.312% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -70.782% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 41.906% |
| Mobile Lads Corp. | -2.24 Million USD | 71.072% |
| CytoDyn Inc. | -18.02 Million USD | 96.404% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -720.362% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -5201.529% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -33.488% |
| SYBLEU INC | -141.57 Thousand USD | -357.95% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 38.953% |
| International Stem Cell Corporation | 202 Thousand USD | 420.952% |
| Bioxytran, Inc. | -3.82 Million USD | 83.029% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1131.619% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 73.666% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 98.193% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -1340.72% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 76.321% |
| Neutra Corp. | -181.24 Thousand USD | -257.702% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 96.784% |
| PureTech Health plc | -11.62 Million USD | 94.424% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 96.784% |
| IXICO plc | -707 Thousand USD | 8.299% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 91.564% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 98.659% |
| CSL Limited | 4.73 Billion USD | 100.014% |
| Cellectis S.A. | -92.63 Million USD | 99.3% |